NCI Community Oncology Research Program - Kansas City (NCORP-KC)
NCI Community Oncology Research Program - Kansas City (NCORP-KC)




Leukemia Clinical Trials

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

 

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.



Acute

Alliance A041701 - "A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy."

CANCER TYPE: Acute
RESEARCH BASE: Alliance
NCT NUMBER: NCT03701308
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 03/06/2019 (22:41:33)

BRIEF DESCRIPTION

AML, adults ≥ 60, Daunorubicin + Cytarabine +/- Uproleselan






ECOG-ACRIN E1910 - "A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults"

CANCER TYPE: Acute
RESEARCH BASE: CTSU E1910
NCT NUMBER: 02003222
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 03/29/2019 (18:31:33)

BRIEF DESCRIPTION

ALL, new dx, B-lineage BCR/ABL negative, age >=30 & <=70, BM & perip blood must be submitted pre-regist; Eval of Blinatumomab.  DCP-001 Eligible






Chronic

Alliance A041702 - A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

CANCER TYPE: Chronic
RESEARCH BASE: Alliance
NCT NUMBER: NCT03737981
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 05/09/2019 (14:15:32)

BRIEF DESCRIPTION

CLL, ≥ 70 years of age, Ibrutinib + Obinutuzumab +/- Venetoclax






SWOG S1712 - " A Randomized Phase II Study of Ruxolitinib in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Evidence of Molecular Disease.

CANCER TYPE: Chronic
RESEARCH BASE: SWOG
NCT NUMBER:
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 02/22/2019 (22:09:33)

BRIEF DESCRIPTION

CML w/molecular disease, Dasatinib or Nilotinib +/- Ruxolitinib.  DCP-001 Eligible









  © 2013-2019 All Rights Reserved. Privacy Policy | Terms & Conditions
NCI Community Oncology Research Program - Kansas City (NCORP-KC)
Questions? Call: +1-913-948-5588 | Contact Us
4121 W. 83rd St., Suite 259 Prairie Village, KS 66208 USA